TCT-15 Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients undergoing primary percutaneous coronary intervention: 3 Year follow-up from the COMPARE II trial  by Vlachojannis, Georgios J. et al.
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMTCT-15
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer
everolimus-eluting stent in patients undergoing primary percutaneous coronary
intervention: 3 Year follow-up from the COMPARE II trial
Georgios J. Vlachojannis1, Pieter C. Smits2, Sjoerd H. Hofma3, Mario Togni4,
Nicolas Vazquez5, Mariano Valdes6, V. Voudris7, Ton Slagboom8,
Jean-Jacques Goy4, A. G. Vuillomenet9, Antonio Serra10, Ramiro Trillo11,
Peter den Heijer12, Martin van der Ent1
1Maasstad Hospital, Rotterdam, Netherlands, 2Maasstad Hospital Rotterdam,
Rotterdam, Netherlands, 3Medical Center Leeuwarden, Leeuwarden, Netherlands,
4Hospital and University Fribourg, Switzerland, Fribourg, Switzerland, 5Hospital
Juan Canalejo, A Coruña, Spain, 6Hospital Universitario Virgen de la Arrixaca,
Murcia, Spain, 7Onassis Cardiac Surgery Centre, Athens, Greece, 8Onze Lieve
Vrouwe Gasthuis, Amsterdam, Netherlands, 9Kantonsspital Aarau, Aarau,
Switzerland, 10Hospital de Sant Pau y Santa Creu, Barcelona, Spain, 11Hospital
Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain,
12Amphia Hospital Breda, Breda, NB
Background: Drug-eluting stents with biodegradable polymers have been developed
to address the risk of very late adverse events. The purpose of this analysis was to
compare safety and efﬁcacy of the biodegradable polymer-coated biolimus-eluting
stent (Nobori; BES) to the durable polymer-coated everolimus-eluting stent
(Xience or Promus; EES) in patients treated with primary percutaneous coronary
intervention (PCI) for ST-elevating myocardial infarction (STEMI).
Methods: The COMPARE II study is an open-label, prospective, randomized, non-
inferiority, all-comers trial undertaken at 12 sites across Europe currently at 3-year
follow-up. Patients were randomly allocated (2:1) to receive either BES or EES. We
performed a sub-analysis of patients treatedwith primary PCI. The pre-speciﬁed endpoint
major adverse cardiovascular event (MACE) was a composite of the safety endpoints
cardiac death or non-fatal myocardial infarction (MI) and the efﬁcacy endpoint clinically
indicated target vessel revascularization (CI-TVR), analyzed by intention to treat.
Results: Of the 2707 study patients, 569 patients (21%) underwent primary PCI for
STEMI with 372 treated with BES and 197 with EES. The 3-year outcomes for pa-
tients undergoing primary PCI with BES or EES are tabulated.Events at 3 years
EES
(n¼197)
BES
(n¼372)
Relative Risk
[95% CI] p-value
All-cause Death 3.6% (7) 4.3% (16) 1.21 [0.51-
2.89]
0.67
Cardiac Death 3.0% (6) 2.7% (10) 0.88 [0.33-
2.39]
0.80
Myocardial Infarction 3.6% (7) 3.8% (14) 1.06 [0.43-
2.58]
0.90
Target Vessel
Revascularization (Any)
2.0% (4) 6.2% (23) 3.05 [1.07-
8.68]
0.03
Target Vessel
Revascularization (CI)
2.0% (4) 4.6% (17) 2.25 [0.77-
6.60]
0.13
Target Lesion
Revascularization (Any)
1.5% (3) 5.1% (19) 3.35 [1.00-
11.19]
0.03
Target Lesion
Revascularization (CI)
1.5% (3) 4.0% (15) 2.65 [0.77-
9.03]
0.10
Def./Prob. Stent Thrombosis 1.5% (3) 1.9% (7) 1.24 [0.32-
4.73]
0.76
Deﬁnite Stent Thrombosis 0.5% (1) 1.9% (7) 3.71 [0.46-
29.91]
0.19
Very Late Def./Prob. Stent
Thrombosis
1.0% (2) 1.1% (4) 1.06 [0.20-
5.73]
0.95
MACE 7.1% (14) 8.3% (31) 1.17 [0.64-
2.15]
0.61Conclusions: At 3-year follow-up the biodegradable polymer-coated BES displayed
similar incidence of the pre-speciﬁed endpoint MACE compared to the durable
polymer-coated EES in patients treated with primary PCI, yet showed higher rates of
target vessel and target lesion revascularizations.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AcTCT-16
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Background: In the setting of successfully reperfused acute ST elevation
myocardial infarction (STEMI) we hypothesized that thermodilution-derived index of
microcirculatory resistance (IMR) measured after primary percutaneous coronary inter-
vention (PCI), may be useful to predict LV remodeling 6months after successful coronary
reperfusion.
Methods: We prospectively enrolled 89 patients (age 529 years; 86% male)
with anterior STEMI. All patients were successfully treated by PCI with establishment
of Thrombolysis In Myocardial Infarction (TIMI) 3 ﬂow after PCI. The thermodilu-
tion-derived index of microcirculatory resistance (IMR) was thereafter measured by
using the pressure-temperature sensor-tipped coronary wire at the left anterior
descending artery (LAD). Angiographic parameters such as TIMI ﬂow and blush
grade were also recorded. Baseline comprehensive cardiovascular magnetic resonance
(CMR) was performed before discharge and at 6 months follow-up. Comprehensive
CMR included cine, T2-weighted, and late gadolinium enhancement (LGE) imaging.
Infarct size (IS) and microvascular obstruction (MVO) were correlated to IMR mea-
surements. LV remodelling was deﬁned as a >20% increase of LV volume at 6
months.
Results: LV remodelling was observed in 34.8% of the patients (31/89). TIMI ﬂow
and blush grade after PCI was not different between patients with and without
LV remodeling (3 for TIMI ﬂow and 2 for Blush grade respectively, p ¼ 0.952).
IMR level markedly differed between patients with and without LV remodeling (73,95
vs. 27,23 p¼0,0293). After multivariate analysis IMR>40 was the strongest angio-
graphic parameter to predict LV remodeling (OR15 (1,030-218,4), p¼0,03).Regarding
CMR, patients with LV remodeling had lower LVEF (43% vs. 48%; p ¼ 0.01), larger
infarct size (IS) (51 mg vs 32 mg; p ¼ 0.002) and greater microvascular obstruction
(MVO) extent (4.5seg vs. 2seg; p ¼ 0.03) when compared to patients with no LV
remodeling.
Conclusions: IMR assessed by coronary angiogram after successful PCI in the setting
of acute STEMI is a strong predictive factor of LV remodeling 6 months after suc-
cessful reperfused AMI.
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Background: There is conﬂicting evidence as to whether direct stenting (DS) is su-
perior to balloon angioplasty with subsequent stenting (conventional stenting, CS) in
patients presenting with ST-elevation myocardial infarction (STEMI). This study
aimed at comparing DS and CS in STEMI using a systematic review and meta-
analysis of published evidence.
Methods: We searched EMBASE, MEDLINE and CENTRAL, from inception of
each database to April 2014. The primary endpoint was mortality. Secondary end-
points included major adverse cardiac events (MACEs), ST-segment resolution on
ECG, and angiographic outcomes.
Results: A total of 9,331 patients enrolled in 12 studies (3 randomized controlled
trials, RCTs; 9 non-randomized studies, NRSs) were included. DS was associated with
lower mortality compared to CS (OR 0.55; 95% CI: 0.33 to 0.94; p¼0.03) in NRSs,
and overall (OR 0.56; 95% CI: 0.37 to 0.86; p¼0.008), as shown in the Figure.
Mortality was non-signiﬁcantly reduced in RCTs (OR 0.56; 95% CI: 0.26 to 1.23;
p¼0.15). DS was also associated with lower MACE rate (OR 0.69; 95% CI 0.54 to
0.87; p¼0.002) in NRSs, but not in RCTs (OR 0.82; 95% CI: 0.38 to 1.77; p¼0.62).
ST-segment resolution, no reﬂow, ﬁnal thrombolysis in myocardial infarction (TIMI)
ﬂow grade and ﬁnal TIMI myocardial perfusion or blush grade were signiﬁcantly
better with DS in NRSs, and non-signiﬁcantly better in RCTs.ute Myocardial Infarction B5
